Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference facilitator today for Amgen’s Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen: Q4 Earnings Snapshot
The Thousand Oaks, California-based company said it had net income of $1.16 per share. Earnings, adjusted for non-recurring costs, came to $5.31 per share. The results surpassed Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share.
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
Amgen's SWOT analysis: stock outlook amid obesity drug race
Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...
Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains
Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.
Amgen expands global capability centre in Hyderabad with 500,000 sq ft lease
Amgen leases 500,000 sq ft in Hyderabad to establish its first global capability centre, enhancing its office space in the ...
Yahoo Finance3d
Is Amgen Inc. (AMGN) the Best Cancer Stock to Buy According to Hedge Funds?
In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best cancer stocks to buy. Cancer is the second leading cause of death across the globe ...
Amgen Inc. stock outperforms competitors on strong trading day
Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.
Barchart on MSN2d
Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?
With a market cap of $153.4 billion, Amgen Inc. (AMGN) is a global leader in biotechnology, focusing on innovative human ...